source_schedule_code int64 4.49k 4.49k | target_effective_date stringdate 2025-08-01 00:00:00 2025-08-01 00:00:00 | source_effective_date stringdate 2025-07-01 00:00:00 2025-07-01 00:00:00 | target_revision_number int64 1 1 | source_revision_number int64 2 2 | target_publication_status stringclasses 1
value | source_publication_status stringclasses 1
value | changed_table stringclasses 20
values | changed_endpoint stringclasses 20
values | change_type stringclasses 3
values | sql_statement stringlengths 84 17.2k | table_keys stringlengths 5 53 | change_detail stringlengths 14 16.7k ⌀ | previous_detail stringlengths 14 17k ⌀ | deleted_ind stringclasses 2
values | new_ind stringclasses 2
values | modified_ind stringclasses 2
values | schedule_code int64 3.77k 3.77k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,489 | 2025-08-01 | 2025-07-01 | 1 | 2 | EMBARGO | PUBLISHED | PRESCRIBING_TXT_T | prescribing-texts | INSERT | INSERT INTO PRESCRIBING_TXT_T([SCHEDULE_CODE],[PRESCRIBING_TXT_ID],[PRESCRIBING_TYPE],[PRESCRIBING_TXT],[PRSCRBG_TXT_HTML],[COMPLEX_AUTHORITY_RQRD_IND],[ASSESSMENT_TYPE_CODE],[APPLY_TO_INCREASE_MQ_FLAG],[APPLY_TO_INCREASE_NR_FLAG]) VALUES (3773 , 33846 , ''ADMINISTRATIVE_ADVICE'' , ''Pharmaceutical benefits that have t... | 377333846 | 377333846ADMINISTRATIVE_ADVICEPharmaceutical benefits that have the form omalizumab 75 mg/0.5 mL syringe and pharmaceutical benefits that have the form omalizumab 75 mg/0.5 mL pen device are equivalent for the purposes of substitution.<p align="justify">Pharmaceutical benefits that have the form omalizumab 75 mg/0.5 mL... | null | N | Y | N | 3,773 |
4,489 | 2025-08-01 | 2025-07-01 | 1 | 2 | EMBARGO | PUBLISHED | PRESCRIBING_TXT_T | prescribing-texts | INSERT | INSERT INTO PRESCRIBING_TXT_T([SCHEDULE_CODE],[PRESCRIBING_TXT_ID],[PRESCRIBING_TYPE],[PRESCRIBING_TXT],[PRSCRBG_TXT_HTML],[COMPLEX_AUTHORITY_RQRD_IND],[ASSESSMENT_TYPE_CODE],[APPLY_TO_INCREASE_MQ_FLAG],[APPLY_TO_INCREASE_NR_FLAG]) VALUES (3773 , 33847 , ''ADMINISTRATIVE_ADVICE'' , ''Pharmaceutical benefits that have t... | 377333847 | 377333847ADMINISTRATIVE_ADVICEPharmaceutical benefits that have the form omalizumab 150 mg/mL syringe and pharmaceutical benefits that have the form omalizumab 150 mg/mL pen device are equivalent for the purposes of substitution.<p align="justify">Pharmaceutical benefits that have the form omalizumab 150 mg/mL syringe ... | null | N | Y | N | 3,773 |
4,489 | 2025-08-01 | 2025-07-01 | 1 | 2 | EMBARGO | PUBLISHED | PRESCRIBING_TXT_T | prescribing-texts | INSERT | INSERT INTO PRESCRIBING_TXT_T([SCHEDULE_CODE],[PRESCRIBING_TXT_ID],[PRESCRIBING_TYPE],[PRESCRIBING_TXT],[PRSCRBG_TXT_HTML],[COMPLEX_AUTHORITY_RQRD_IND],[ASSESSMENT_TYPE_CODE],[APPLY_TO_INCREASE_MQ_FLAG],[APPLY_TO_INCREASE_NR_FLAG]) VALUES (3773 , 33848 , ''PRESCRIBING_INSTRUCTIONS'' , ''Applications for authorisation m... | 377333848 | 377333848PRESCRIBING_INSTRUCTIONSApplications for authorisation must be made in writing and must include: (1) details of the two proposed prescriptions; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administra... | null | N | Y | N | 3,773 |
4,489 | 2025-08-01 | 2025-07-01 | 1 | 2 | EMBARGO | PUBLISHED | PRESCRIBING_TXT_T | prescribing-texts | INSERT | INSERT INTO PRESCRIBING_TXT_T([SCHEDULE_CODE],[PRESCRIBING_TXT_ID],[PRESCRIBING_TYPE],[PRESCRIBING_TXT],[PRSCRBG_TXT_HTML],[COMPLEX_AUTHORITY_RQRD_IND],[ASSESSMENT_TYPE_CODE],[APPLY_TO_INCREASE_MQ_FLAG],[APPLY_TO_INCREASE_NR_FLAG]) VALUES (3773 , 33849 , ''PRESCRIBING_INSTRUCTIONS'' , ''Applications for authorisation m... | 377333849 | 377333849PRESCRIBING_INSTRUCTIONSApplications for authorisation must be made in writing and must include: (1) details of the two proposed prescriptions; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administra... | null | N | Y | N | 3,773 |
4,489 | 2025-08-01 | 2025-07-01 | 1 | 2 | EMBARGO | PUBLISHED | ITEM_T | items | UPDATE | UPDATE ITEM_T SET [DRUG_NAME]=''Tocilizumab'' , [LI_DRUG_NAME]=''Tocilizumab'' , [LI_FORM]=''Concentrate for injection 200 mg in 10 mL'' , [SCHEDULE_FORM]=''tocilizumab 200 mg/10 mL injection, 10 mL vial'' , [BRAND_NAME]=''Actemra'' , [PROGRAM_CODE]=''HS'' , [PBS_CODE]=''13716X'' , [BENEFIT_TYPE_CODE]=''S'' , [CAUTION_... | 377313716X_8853_1373_5889_7175 | 377313716X_8853_1373_5889_7175TocilizumabTocilizumabConcentrate for injection 200 mg in 10 mLtocilizumab 200 mg/10 mL injection, 10 mL vialActemraHS13716XSNYINJECTION115102RO11N200.71200.71N20NNNNNNNYNNY121212NF2NinjectableNNNNN2023-11-01NY200.71Injection | 448913716X_8853_1373_5889_7175TocilizumabTocilizumabConcentrate for injection 200 mg in 10 mLtocilizumab 200 mg/10 mL injection, 10 mL vialActemraHS13716XSNYINJECTION115102RO11N203.73203.73N20NNNNNNNYNNY121212NF2NinjectableNNNNN2023-11-01NY203.73Injection | N | N | Y | 3,773 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.